These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37400350)

  • 1. Lean tissue mass measurements by dual-energy X-ray absorptiometry and associations with strength and functional outcome measures in facioscapulohumeral muscular dystrophy.
    Wang LH; Leung DG; Wagner KR; Lowry SJ; McDermott MP; Eichinger K; Higgs K; Walker M; Lewis L; Martens WB; Mul K; Sansone VA; Shieh P; Elsheikh B; LoRusso S; Butterfield RJ; Johnson N; Preston MR; Messina C; Carraro E; Tawil R; Statland J;
    Neuromuscul Disord; 2023 Sep; 33(9):63-68. PubMed ID: 37400350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study.
    LoRusso S; Johnson NE; McDermott MP; Eichinger K; Butterfield RJ; Carraro E; Higgs K; Lewis L; Mul K; Sacconi S; Sansone VA; Shieh P; van Engelen B; Wagner K; Wang L; Statland JM; Tawil R;
    BMC Neurol; 2019 Sep; 19(1):224. PubMed ID: 31506080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between regional body composition and quantitative strength in facioscapulohumeral muscular dystrophy (FSHD).
    Skalsky AJ; Abresch RT; Han JJ; Shin CS; McDonald CM
    Neuromuscul Disord; 2008 Nov; 18(11):873-80. PubMed ID: 18818077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resting metabolic rate in adults with facioscapulohumeral muscular dystrophy.
    Vera K; McConville M; Kyba M; Keller-Ross M
    Appl Physiol Nutr Metab; 2021 Sep; 46(9):1058-1064. PubMed ID: 33735584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy.
    Wang LH; Shaw DWW; Faino A; Budech CB; Lewis LM; Statland J; Eichinger K; Tapscott SJ; Tawil RN; Friedman SD
    BMC Musculoskelet Disord; 2021 Mar; 22(1):262. PubMed ID: 33691664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal study of disease progression in facioscapulohumeral muscular dystrophy (FSHD).
    Varma A; Todinca MS; Eichinger K; Heininger S; Dilek N; Martens W; Tawil R; Statland J; Kissel JT; McDermott MP; Heatwole C
    Muscle Nerve; 2024 Mar; 69(3):362-367. PubMed ID: 38189531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between whole body muscle MRI and functional measures in paediatric patients with facioscapulohumeral muscular dystrophy.
    Woodcock IR; de Valle K; Varma N; Kean M; Ryan MM
    Neuromuscul Disord; 2023 Jan; 33(1):15-23. PubMed ID: 36522253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy.
    Leung DG; Carrino JA; Wagner KR; Jacobs MA
    Muscle Nerve; 2015 Oct; 52(4):512-20. PubMed ID: 25641525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients.
    Andersen G; Dahlqvist JR; Vissing CR; Heje K; Thomsen C; Vissing J
    J Neurol; 2017 Mar; 264(3):438-447. PubMed ID: 28000006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report.
    Wang LH; Johnstone LM; Bindschadler M; Tapscott SJ; Friedman SD
    BMC Musculoskelet Disord; 2021 Jan; 22(1):56. PubMed ID: 33422031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome.
    Vincenten SCC; Mul K; van As D; Jansen JJ; Heskamp L; Heerschap A; van Engelen BGM; Voermans NC
    J Cachexia Sarcopenia Muscle; 2023 Aug; 14(4):1695-1706. PubMed ID: 37218549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials.
    Ghasemi M; Emerson CP; Hayward LJ
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group.
    Kissel JT; McDermott MP; Natarajan R; Mendell JR; Pandya S; King WM; Griggs RC; Tawil R
    Neurology; 1998 May; 50(5):1402-6. PubMed ID: 9595995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging.
    Monforte M; Laschena F; Ottaviani P; Bagnato MR; Pichiecchio A; Tasca G; Ricci E
    J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1258-1265. PubMed ID: 31668022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of regional body composition with dual-energy X-ray absorptiometry in Duchenne muscular dystrophy: correlation of regional lean mass and quantitative strength.
    Skalsky AJ; Han JJ; Abresch RT; Shin CS; McDonald CM
    Muscle Nerve; 2009 May; 39(5):647-51. PubMed ID: 19347922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone health in facioscapulohumeral muscular dystrophy: A cross-sectional study.
    Chagarlamudi H; Corbett A; Stoll M; Bibat G; Grosmann C; Matichak Stock C; Stinson N; Shapiro J; Wagner KR
    Muscle Nerve; 2017 Dec; 56(6):1108-1113. PubMed ID: 28214289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy.
    Vera KA; McConville M; Kyba M; Keller-Ross ML
    Front Physiol; 2020; 11():1008. PubMed ID: 32903446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the role of muscle ultrasound as an imaging biomarker in facioscapulohumeral muscular dystrophy.
    Vincenten SCC; Teeselink S; Voermans NC; van Engelen BGM; Mul K; van Alfen N
    Neuromuscul Disord; 2023 Dec; 33(12):936-944. PubMed ID: 37968164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscle MRI of facioscapulohumeral dystrophy (FSHD): A growing demand and a promising approach.
    Fatehi F; Salort-Campana E; Le Troter A; Bendahan D; Attarian S
    Rev Neurol (Paris); 2016 Oct; 172(10):566-571. PubMed ID: 27663058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).
    Goselink RJ; Schreuder TH; Mul K; Voermans NC; Pelsma M; de Groot IJ; van Alfen N; Franck B; Theelen T; Lemmers RJ; Mah JK; van der Maarel SM; van Engelen BG; Erasmus CE
    BMC Neurol; 2016 Aug; 16():138. PubMed ID: 27530735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.